Back to search

Peptide record

TPDB92089

NK-2 Antibacterial Anticancer Antifungal Antiparasitic Toxicity standard
27 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB92089
NK-2
Antibacterial Anticancer Antifungal Antiparasitic Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP dbAMP 3.0 iACP-DRLF CAFPdb i2APP
standard
No
A 27-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
C-terminal: Amidation
Sequence
KILRGVCKKIMRTFLRRISKDILTGKK-NH2
Physicochemical Analysis
C143H261N45O33S2
ANEQHPWY
K
3203.05
12.02
10
1
10
+9
6.39
-0.263
111.85
Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min
0
0.00
4
Residue Composition
number
0
A
4
R
0
N
1
D
1
C
0
E
0
Q
2
G
0
H
4
I
3
L
6
K
1
M
1
F
0
P
1
S
2
T
0
W
0
Y
1
V
Amino Acid Distribution
A: 0 R: 4 N: 0 D: 1 C: 1 E: 0 Q: 0 G: 2 H: 0 I: 4 L: 3 K: 6 M: 1 F: 1 P: 0 S: 1 T: 2 W: 0 Y: 0 V: 1
Chemical Descriptors
27
C143H261N45O33S2
3203.05
12.02
+9
6.39
-0.263
Amidation
L
Linear
Free
Antibacterial Antimicrobial Anticancer
NK-lysin Synthetic peptide Residue of 39-65 of porcine NK-lysine
Evidence Records 13 records
Evidence 1 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Colorectal Cancer
NB LA-N-1
Colon

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 2 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Brain Tumor
SH-SY5Y
Brain

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 3 Activity

Activity

LD50
LD50=30 µM
Anticancer
30 µM

Target

Lymphoma Cancer
U-937
Blood

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 4 Activity

Activity

LD50
LD50=1-4 µM
Anticancer
1-4 µM

Target

Leukemia Cancer
SW-480
Blood

Assay & Model

PI-uptake assay
Not Available

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
Evidence 5 Activity

Activity

IC50
IC50 = ~70 µM
Anticancer
~70 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 6 Activity

Activity

IC50
IC50 = ~50 µM
Anticancer
~50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 7 Activity

Activity

IC50
IC50 = ~50 µM
Anticancer
~50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 8 Activity

Activity

IC50
IC50 = ~40 µM
Anticancer
~40 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 9 Activity

Activity

IC50
IC50= 4.3±0.3 µM
Anticancer
4.3

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 10 Activity

Activity

IC50
IC50= 70 µM (approx)
Anticancer
70 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
30-Min

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 11 Activity

Activity

IC50
IC50= 50 µM (approx)
Anticancer
50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
2-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 12 Activity

Activity

IC50
IC50= 50 µM (approx)
Anticancer
50 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
4-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013
Evidence 13 Activity

Activity

IC50
IC50= 40 µM (approx)
Anticancer
40 µM

Target

Skin Cancer
E42/02
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2013